|4Mar 27, 8:23 PM ET

CMEA VENTURES VI LP 4

4 · TETRAPHASE PHARMACEUTICALS INC · Filed Mar 27, 2013

Insider Transaction Report

Form 4
Period: 2013-03-25
Transactions
  • Conversion

    Common Stock

    2013-03-25+23,63936,790 total
  • Purchase

    Common Stock

    2013-03-25$7.00/sh+628,071$4,396,4972,157,130 total
  • Conversion

    Series A-2 Convertible Participating Preferred Stock

    2013-03-252,662,0590 total
    Common Stock (91,795 underlying)
  • Conversion

    Series C Convertible Participating Preferred Stock

    2013-03-25685,5310 total
    Common Stock (23,639 underlying)
  • Conversion

    Common Stock

    2013-03-25+1,6931,693 total
  • Conversion

    Common Stock

    2013-03-25+91,795162,171 total
  • Conversion

    Common Stock

    2013-03-25+9,25013,151 total
  • Conversion

    Series A-1 Convertible Participating Preferred Stock

    2013-03-2549,0880 total
    Common Stock (1,693 underlying)
  • Conversion

    Series A-1 Convertible Participating Preferred Stock

    2013-03-252,040,9120 total
    Common Stock (70,376 underlying)
  • Conversion

    Common Stock

    2013-03-25+70,37670,376 total
  • Conversion

    Common Stock

    2013-03-25+2,2083,901 total
  • Conversion

    Common Stock

    2013-03-25+384,613546,784 total
  • Purchase

    Common Stock

    2013-03-25$7.00/sh+14,786$103,50251,576 total
  • Conversion

    Series B Convertible Participating Preferred Stock

    2013-03-25268,2690 total
    Common Stock (9,250 underlying)
  • Conversion

    Common Stock

    2013-03-25+982,2751,529,059 total
  • Conversion

    Series A-2 Convertible Participating Preferred Stock

    2013-03-2564,0270 total
    Common Stock (2,208 underlying)
  • Conversion

    Series B Convertible Participating Preferred Stock

    2013-03-2511,153,7760 total
    Common Stock (384,613 underlying)
  • Conversion

    Series C Convertible Participating Preferred Stock

    2013-03-2528,485,9970 total
    Common Stock (982,275 underlying)
Footnotes (4)
  • [F1]The Series A-1, Series A-2, Series B and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-29 basis upon the closing of the issuer's initial public offering without payment of consideration.
  • [F2]Held by CMEA Ventures VI, GmbH & Co. KG. The general partner of CMEA Ventures VI, GmbH & Co. KG is CMEA Ventures VI Management, L.P. The general partners of CMEA Ventures VI Management, L.P. are Karl Handelsman, David Collier, Faysal Sohail, Thomas Baruch and James Watson. CMEA Ventures VI Management, L.P. and each of these individuals exercises shared voting and investment power over the shares held of record by CMEA Ventures VI, GmbH & Co. KG. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  • [F3]Held by CMEA Ventures VI, L.P. The general partner of CMEA Ventures VI, L.P. is CMEA Ventures VI Management, L.P. The general partners of CMEA Ventures VI Management, L.P. are Karl Handelsman, David Collier, Faysal Sohail, Thomas Baruch and James Watson. CMEA Ventures VI Management, L.P. and each of these individuals exercises shared voting and investment power over the shares held of record by CMEA Ventures VI, L.P. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  • [F4]Not applicable.

Documents

1 file
  • 4
    rrd374462.xmlPrimary

    FORM 4